Skip to main content

Research Repository

Advanced Search

All Outputs (31)

A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer (2011)
Journal Article
ELFadl, D., Hodgkinson, V. C., Long, E. D., Scaife, L., Drew, P. J., Lind, M. J., & Cawkwell, L. (2011). A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer. The Breast : official journal of the European Society of Mastology, 20(4), 334-337. https://doi.org/10.1016/j.breast.2011.02.017

Breast conserving therapy is a currently accepted method for managing patients with early stage breast cancer. However, approximately 7% of patients may develop loco-regional tumour recurrence within 5 years. We previously reported that expression of... Read More about A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer.

Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis (2011)
Journal Article
Hodgkinson, V. C., ELFadl, D., Drew, P. J., Lind, M. J., & Cawkwell, L. (2011). Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis. Journal of Proteomics, 74(5), 698-703. https://doi.org/10.1016/j.jprot.2011.02.014

Antibody microarrays are powerful new tools in the field of comparative proteomics. The success of the biomarker discovery pipeline relies on the quality of data generated in the discovery phase and careful selection of proteins for the verification... Read More about Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis.

Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand? (2010)
Journal Article
Agarwal, V., Lind, M. J., & Cawkwell, L. (2011). Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?. Cancer Treatment Reviews, 37(7), 533-542. https://doi.org/10.1016/j.ctrv.2010.11.004

The median survival for patients with malignant pleural mesothelioma remains extremely poor and there is a need for the development of more effective treatment modalities. The epidermal growth factor receptor is frequently over-expressed in malignant... Read More about Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?.

Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy (2010)
Journal Article
Murray, A., Little, S. J., Stanley, P., Cawkwell, L., & Maraveyas, A. (2010). Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy. Oncology Reports, 24(4), 1049-1058. https://doi.org/10.3892/or-00000954

Angiogenesis inhibitors may enhance the effects of low dose (metronomic) chemotherapy. However, there is a wide range of novel angiogenesis inhibitors which must be tested in combinations with oral chemotherapy agents to assess the anti-endothelial a... Read More about Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.

Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status (2010)
Journal Article
Hodgkinson, V. C., Eagle, G. L., Drew, P. J., Lind, M. J., & Cawkwell, L. (2010). Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status. Cancer Letters, 294(1), 13-24. https://doi.org/10.1016/j.canlet.2010.01.036

This review describes and discusses the advantages and limitations of proteomic approaches in the identification of biomarkers associated with chemotherapy resistance. Both gel-based (two-dimensional polyacrylamide gel electrophoresis) and gel-free (... Read More about Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status.

Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome? (2009)
Journal Article
Smith, L., Qutob, O., Watson, M. B., Beavis, A. W., Potts, D., Welham, K. J., …Cawkwell, L. (2009). Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome?. Neoplasia, 11(11), 1194-1207. https://doi.org/10.1593/neo.09902

PURPOSE: We aimed to identify putative predictive protein biomarkers of radioresistance. EXPERIMENTAL DESIGN: Three breast cancer cell lines (MCF7, MDA-MB-231, and T47D) were used as in vitro models to study radioresistance. Inherent radiosensitiviti... Read More about Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome?.

COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines (2009)
Journal Article
O'Kane, S. L., Eagle, G. L., Greenman, J., Lind, M. J., & Cawkwell, L. (2010). COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer, 67(2), 160-165. https://doi.org/10.1016/j.lungcan.2009.04.008

BACKGROUND Although malignant pleural mesothelioma is a rare tumour, its incidence is increasing. The prognosis remains very poor with an average survival of 10 months from diagnosis. The choice of chemotherapy regimens for mesothelioma patients is l... Read More about COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.

The proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia (2009)
Thesis
Eagle, G. L. (2009). The proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4209165

Chronic Lymphocytic Leukaemia (CLL) is the most common adult Leukaemia in the UK, Western Europe and America. It is a malignancy of naive B-cells. The clinical course of patients with CLL is heterogeneous; some patients survive for years without trea... Read More about The proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia.

Radioresistance in oral squamous cell carcinoma (2008)
Thesis
Murphy, J. T. (2008). Radioresistance in oral squamous cell carcinoma. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4208413

Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most common cancer accounting for approximately 6% of all cancers worldwide. However the distribution across the globe varies considerably. The majority of small tumours of the oral cavity an... Read More about Radioresistance in oral squamous cell carcinoma.

The proteomic analysis of resistance to anticancer therapy in human breast cancer (2006)
Thesis
Smith, L. (2006). The proteomic analysis of resistance to anticancer therapy in human breast cancer. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4212607

Resistance to anticancer therapy represents a major barrier in the successful management of human breast cancer. The identification of novel biomarkers that correlate with treatment response would increase our understanding of the resistance mechanis... Read More about The proteomic analysis of resistance to anticancer therapy in human breast cancer.

The role of chromosome 22 in the progression of head and neck squamous cell carninoma (2003)
Thesis
Condon, L. T. (2003). The role of chromosome 22 in the progression of head and neck squamous cell carninoma. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4223891

Head and neck squamous cell carcinoma (HNSCC) is one o f the ten most frequent cancers in the world. Despite advances in surgery, radiotherapy and chemotherapy over the last 30 years, there has been little improvement in the mortality rate from this... Read More about The role of chromosome 22 in the progression of head and neck squamous cell carninoma.